SCHEMBL759898

SCHEMBL759898

N[C@H](CN1CCCC1)[C@H](O)c1ccc(O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGCG Q16739 1/20 0.47
CYP1A2 P05177 2/20 0.42
NFKB1 P19838 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP3A4 P08684 1/20 0.42
MAPK1 P28482 1/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
ADRA1D P25100 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42
MTOR P42345 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
GMNN O75496 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16695337 0.85 POLB (0.55) CYP1A2CYP2D6CYP3A4MAPK1ADRA1A
SCHEMBL19795864 0.85 HRH3 (0.47) UGCGLMNAPOLBTSHRKMT2A
SCHEMBL18012030 0.85 MEN1 (0.49) UGCGKMT2AMEN1ACHEKDM4E
SCHEMBL7679162 0.85 ALDH1A1 (0.49) UGCGCYP2D6MAPK1POLBTSHR
SCHEMBL17016723 0.83 ALDH1A1 (0.49) UGCGCYP2D6MAPK1POLBTSHR
SCHEMBL21648644 0.83 TDP1 (0.56) CYP1A2NFKB1CYP3A4MAPK1ADRA1D
SCHEMBL13267946 0.82 UGCG (0.38) UGCGCYP1A2NFKB1CYP2D6CYP3A4
SCHEMBL1372724 0.82 LTA4H (0.46) CYP1A2CYP2D6CYP3A4POLBTSHR
SCHEMBL12151256 0.82 LTA4H (0.46) CYP1A2CYP2D6CYP3A4POLBTSHR
SCHEMBL12000777 0.82 LTA4H (0.46) CYP1A2CYP2D6CYP3A4POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171507-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS GENZYME CORPORATION 2021-06-10 US disclosed
EP-3253734-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2020-12-23 EP disclosed
US-20190322649-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS GENZYME CORPORATION 2019-10-24 US disclosed
US-10202340-B2 Glucosylceramide synthase inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-02-12 US disclosed
US-20180022697-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2018-01-25 US disclosed
US-20180022697-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2018-01-25 US disclosed
US-9546161-B2 Synthesis of UDP-glucose: N-acylsphingosine glucosyl transferase inhibitors GENZYME CORPORATION (US) 2017-01-17 US disclosed
US-9546161-B2 Synthesis of UDP-glucose: N-acylsphingosine glucosyl transferase inhibitors GENZYME CORPORATION (US) 2017-01-17 US disclosed
WO-2016126572-A2 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-08-11 WO disclosed
US-20150148534-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYL TRANSFERASE INHIBITORS GENZYME CORPORATION 2015-05-28 US disclosed
US-20080058514-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS HIRTH BRADFORD H 2008-03-06 US disclosed
US-20080058514-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS HIRTH BRADFORD H 2008-03-06 US disclosed
US-7265228-B2 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors GENZYME CORPORATION (US) 2007-09-04 US disclosed
US-7265228-B2 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors GENZYME CORPORATION (US) 2007-09-04 US disclosed
US-20070203223-A1 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2007-08-30 US disclosed
US-20070203223-A1 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2007-08-30 US disclosed
US-7196205-B2 Synthesis of amino ceramide-like compounds; for treating Tay-Sachs, Gaucher's or Fabry's disease; amenable to large scale preparations THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2007-03-27 US disclosed
US-7196205-B2 Synthesis of amino ceramide-like compounds; for treating Tay-Sachs, Gaucher's or Fabry's disease; amenable to large scale preparations THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2007-03-27 US disclosed
US-20030050299-A1 An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents GENZYME CORPORATION 2003-03-13 US disclosed
US-20030050299-A1 An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents GENZYME CORPORATION 2003-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022697-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME GBA1, GBA2, GAA UGCG 4/4885CYP1A2 2983/4885NFKB1 3891/4885
US-20210171507-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS UGCG, UGGT1, DPAGT1 UGCG 1/4885CYP1A2 2694/4885NFKB1 3817/4885
US-20150148534-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYL TRANSFERASE INHIBITORS UGCG, UGGT1, DPAGT1 UGCG 1/4885CYP1A2 2765/4885NFKB1 3923/4885
US-10202340-B2 Glucosylceramide synthase inhibitors and therapeutic methods using the same GBA1, GBA2, GAA UGCG 4/4885CYP1A2 2983/4885NFKB1 3891/4885
US-20080058514-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS UGCG, UGGT1, DPAGT1 UGCG 1/4885CYP1A2 2694/4885NFKB1 3817/4885
US-20190322649-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS UGCG, UGGT1, DPAGT1 UGCG 1/4885CYP1A2 2694/4885NFKB1 3817/4885
US-20070203223-A1 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors UGCG, UGGT1, DPAGT1 UGCG 1/4885CYP1A2 2694/4885NFKB1 3817/4885
US-20030050299-A1 An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents UGCG, UGGT1, LCLAT1 UGCG 1/4885CYP1A2 2305/4885NFKB1 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.